Discover
NBTX
Nanobiotix S.A.
39.48
1 x 39.60
2 x 38.00
bid
ask
+
1.78
4.72%
2 @ 04:00 PM
37.25 -2.23 (5.65%)
| Ytd | 70.76% | |
| 1y | 763.89% |
37.16
day range
39.90
4.73
52 week range
57.14
| Open | 37.40 | Prev Close | 37.70 | Low | 37.16 | High | 39.90 | Mkt Cap | 2.01B |
| Vol | 77.23K | Avg Vol | 79.48K | EPS | -0.57 | P/E | N/A | Forward P/E | 489.75 |
| Beta | 0.59 | Short Ratio | 1.02 | Inst. Own | 11.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-31 | 50-d Avg | 38.60 | 200-d Avg | 27.58 | 1yr Est | 43.58 |
NBTX News
seekingalpha.com
Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform
Nanobiotix is rated a strong speculative Buy, driven by risk-adjusted upside from its JNJ-1900 radio
benzinga.com
Leerink Partners Maintains Outperform on Nanobiotix, Raises Price Target to $46
Leerink Partners analyst Jonathan Chang maintains Nanobiotix (NASDAQ:NBTX) with a Outperform and
benzinga.com
Nanobiotix Reports Q1 2026 Progress, Highlights 85.7% Response Rate In Phase 2 JNJ-1900 NSCLC Study,
Completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 milli
benzinga.com
Nanobiotix Added to Euronext Tech Leaders Program and Index
NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic app